- Home
- SEER vs SLN Comparison
SEER vs SLN Comparison
Compare SEER & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- SLN
- Stock Information
- Founded
- SEER 2017
- SLN 1994
- Country
- SEER United States
- SLN United Kingdom
- Employees
- SEER N/A
- SLN N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- SLN Health Care
- Exchange
- SEER Nasdaq
- SLN Nasdaq
- Market Cap
- SEER 124.9M
- SLN 123.3M
- IPO Year
- SEER 2020
- SLN N/A
- Fundamental
- Price
- SEER $1.97
- SLN $3.14
- Analyst Decision
- SEER Hold
- SLN Buy
- Analyst Count
- SEER 1
- SLN 5
- Target Price
- SEER $3.00
- SLN $40.80
- AVG Volume (30 Days)
- SEER 271.4K
- SLN 292.1K
- Earning Date
- SEER 05-07-2025
- SLN 05-15-2025
- Dividend Yield
- SEER N/A
- SLN N/A
- EPS Growth
- SEER N/A
- SLN N/A
- EPS
- SEER N/A
- SLN N/A
- Revenue
- SEER $14,170,000.00
- SLN $43,258,000.00
- Revenue This Year
- SEER $23.54
- SLN N/A
- Revenue Next Year
- SEER $42.98
- SLN N/A
- P/E Ratio
- SEER N/A
- SLN N/A
- Revenue Growth
- SEER N/A
- SLN 36.71
- 52 Week Low
- SEER $1.56
- SLN $1.97
- 52 Week High
- SEER $2.63
- SLN $24.38
- Technical
- Relative Strength Index (RSI)
- SEER 52.65
- SLN 49.25
- Support Level
- SEER $1.97
- SLN $2.63
- Resistance Level
- SEER $2.15
- SLN $2.95
- Average True Range (ATR)
- SEER 0.11
- SLN 0.43
- MACD
- SEER 0.04
- SLN 0.11
- Stochastic Oscillator
- SEER 66.04
- SLN 72.67
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.